Skip to main content

Table 5 Known ocular side effects of prior chemotherapy agents before EGFR and FGFR inhibitor therapy

From: Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors

Prior chemotherpy agents before study drugsMechanism [24,25,26,27,28,29,30,31,32]Known ocular side effects
AfatinibEGFR-inhibitorAnterior uveitis [32]
CapecitabineAntimetabolite/pyrimidine analogdry eye, lacrimation [24],
CisplatinAlkylating agent/platinumBlurred vision, retinotoxicity (retinal ischaemia and neovascularization), optic neuropathy [33]
Doxorubicinanthracyline drugconjunctivitis (m/c), periorbital edema, lacrimation, blepharospasm, keratitis, and decreased visual acuity [34]
EverolimusmTOR inhibitorposterior reversible encephalopathy syndrome,bilateral optic neuropathy [35]
GeftinibEGFR-inhibitorDry eye, corneal ulcer [36, 37]
Gemcitabineantimetabolite agentuveal effusion and outer retinal disruption or Purtscher-like retinopathy with combination of docetaxel [25, 38]
Irinotecantopoisomerase I inhibitorNone [39], none in combination regimen with 5-fluorouracil, oxaliplatin and bevacizumab [40]
Oxaliplatinplatinumdry eye, lacrimation, conjunctivitis, damage of the retinal pigment epithelium and the optic nerve, visual field defect [30, 41]
PaclitaxelAntimicrotubule agentepiphora, eye pain, conjunctivitis, blepharitis, blurred vision [24, 42]
PemetrexedAntimetabolite /antifolateAION [1], eyelid edema [24, 43]
Ramucirumabmonoclonal Ab of VEGFR-2none [28]
Sorafenibanti-VEGF agentblurred vision, periocular edema, retinal detachment, ptosis, optic neuropathy, macular edema [27, 44]
Temozolomidealkylating/methylating agentblurred vision with concurrent radiation therapy [45].
  1. AION Anterior ischemic optic neuropathy, VEGF Vascular endothelial growth factor, Ab Antibody, VEGFR Vascular endothelial growth factor receptor, mTOR mammalian target of rapamycin